Frost & Sullivan Releases the " 2026 Blue Book on the Internationalization of China’s Biopharmaceutical Industry"
China’s biopharmaceutical industry is transitioning from “manufacturing internationalization” toward “innovation-led globalization.” The API, generic drug and biosimilar sectors are continuously upgrading toward higher-value and higher-barrier segments, while innovative medicines are increasingly playing a leading role in internationalization and becoming a key driver of global expansion. Currently, multiple pathways, including independent global development, out-licensing and acquisitions, are advancing in parallel. Cross-border BD activities continue to grow, with differentiated modalities such as ADCs, bispecific antibodies and peptides emerging as major areas of collaboration. Partnership models are evolving from single-product licensing toward platform-based strategic collaborations, enabling deeper integration into the global R&D ecosystem. Despite challenges related to supply chain coordination, increasingly stringent regulatory requirements and global operational capabilities, opportunities are emerging from industrial upgrading, increasingly mature compliance systems and growing international recognition of Chinese biopharmaceutical innovation. Going forward, the industry is expected to achieve steady and progressive international growth, driven by advanced manufacturing capabilities, differentiated innovation and multi-regional global deployment.
